Abstract
The discovery of potent hypothalamic analogues led to extensive laboratory investigations, confirming that both agonistic and antagonistic analogues of luteinizing hormone-releasing hormone (LHRH) had inhibitory effects on rat prostate tumors [1–3]. Excitement generated by this significant finding stimulated implementation of a series of clinical studies in human prostate tumors designed to define the appropriate dose of LHRH analogues, establish a toxicity profile, and evaluate therapeutic activity. With an acceptable toxicity pattern and demonstrable clinical activity, LHRH analogues then entered clinical trials comparing their activity to the established therapeutic interventions, including orchiectomy or oral estrogens, for advanced prostate cancers to evaluate treatment morbidity, tumor responsiveness, time to disease progression, and the ultimate parameter of survival. In this chapter, the data generated by the LHRH clinical investigations in the treatment of prostate cancer will be summarized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schally AV, et al (1980): LH-RH agonists and antagonists. Int J Gynaecol Obstet 18: 318–324.
Sandow J, et al (1978): Pituitary gonadotropin inhibition by a highly active analog of luteininzing hormone-releasing hormone. Fertil Steril 30:205–209.
Auclair C, et al (1977): Potent inhibitory activity of (D-Leu6,Des-Gly-NH2)LH-RH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 101:1890–1893.
1986 Cancer Facts & Figures. New York, American Cancer Society, 1986.
Schmidt JD, Benson RC: Prostatic Carcinoma Epidemiology. Prostatic Carcinoma: Current Concepts and Management. (Monograph) San Diego University of California, pp 3–5.
Anderson KM, Liao S (1968): Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219:277–279.
Bruchovsky N, Wilson (1968): The conversion of testosterone to a 5-α-androstane-17-β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2102–2121.
Horton RJ (1976): Androgen hormones and prehormones in young and elderly men. In Grayhack JT, Wilson JD, Scherbenske MD (eds): Benign Prostatic Hyperplasia: Proceedings of a workshop sponsored by the Kidney Disease and Urology Program on the NIAMDD. Washington, DC, US Government Printing Office, pp 183–188.
Lipsett MB (1970): Steroid secretion by the human testes. In Rosenberg E, Paulson CA (ed): The Human Testes. New York, Plenum pp 407–421.
Catalona WJ (1984): Epidemiology and etiology. In Prostate Cancer. Orlando, FL: Grune & Stratton, pp 1–14.
Sandberg AA (1980): Endocrine control and physiology of the prostate. Prostate 1:169–184.
Walsh PC (1975): Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2:125–140.
Soules MR, Hammond CB (1980): Female Kallmann’s syndrome: evidence for a hypothalamic luteinizing hormone-releasing hormone deficiency. Fertil Steril 33:82–85.
Fraser HM (1980): Inhibition of reproductive function by antibodies to luteinizing hormone-releasing hormone. In Hearn JP (ed): Immunological Aspects of Reproduction and Fertiligy Control. Lancaster, England, MTP Press Ltd, pp 143–171.
Grayhack JT (1963): Pituitary factors influencing growth of the prostate: workshops on the biology of the prostate and related tissues. Natl Cancer Inst Monogr 12:189–199.
Huggins C, Hodges CV (1941): Studies in prostatic cancer. I. The effect of castration estrogens and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293.
Robinson MRG, Thomas BS (1971): Effect of hormonal therapy on plasma tetosterone levels in prostatic carcinoma. Br Med J 4:391–394.
Young JD, Jr, et al (1979): The role of estrogen, androgen and progestogen receptors in the management of carcinoma of the prostate. Trans Am Assoc GU Surg 71:23–25.
Huggins C, Clark PJ (1940): Quantitative studies of prostatic secretion. II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostatic glands of dogs J Exp Med 72:747.
Schally AV, et al (1980): Recent approaches to fertility control based on derivatives of LH-RH. In Munson PL, Glover E, Diczfalusy E, et al (eds): Vitamins and Hormones. New York, Academic Press, p 257–323.
Coy DH, et al (1976): Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem 119: 423–425.
Sandow J (1983): Clinical applicators of LHRH and its analogs. Clin Endocrinol 18:571–592.
Corbin A (1982): From contraception to cancer; a review of the therapeutic applications of LHRH analogs as antitumor agents. Yale J Biol Med 55:27–47.
Trachtenberg J (1982): The effect of the chronic administration of a potent luteinizing hormone-releasing hormone analog on the rat prostate. J Urol 128:1097.
Faure N, et al (1982): Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone releasing hormone (LHRH) agonist in adult men. Fertil Steril 37:416.
Redding TW, Schally AV (1982): Inhibition of prostate tumor growth in two rat models by chronic administration of D-TRP-6 analog of luteinizing hormone releasing hormone. Proc Natl Acad Sci USA 78:6509, 1982.
Labrie F, et al (1986): Combined antiandrogen blockade should be used at all times in all patients with advanced prostate cancer. In Catalona WJ, Ratliff TL (eds): Genitourinary Cancer III. Boston: Martinus N Publ.
Smith JA, et al (1985): Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Unology 25:106, 1985.
Labrie, F, Dupont, A and Bélanger, A (1985). Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology. Ed De Vita, VT, Hellman, S and Rosenberg, SA, pp 193–217. Philadelphia: JB Lippincott.
Ahmed SR, et al (1983): Treatment of advanced prostate cancer with LHRH analog Zoladex. Lancet 2:415–418.
Waxman JH, et al (1984): Treatment will gonadotropin releasing hormone analogue in advanced prostatic cancer. Br Med J 286:1309–1312.
Veterans Administration Cooperative Urological Research Group (1967): Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011–1017.
Leuprolide Study Group (1984): Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286, 1984.
Parmar H (1985): Randomized controlled study of orchiectomy vs. long-acting D-trp-6-LHRH microcapsules in advanced prostate carcinoma. The Lancet 2:1201.
Geller J Albert J, Loza D, et al (1978): DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab. 46:440–444.
Labrie F, Dupont A, Belanger A, et al (1983): New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4:579.
Herr HW, et al (1987): Intermittent hormone therapy for advanced prostate cancer. J Urol 137:255A.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Crawford, E.D., Davis, M.A. (1988). Luteinizing Hormone-Releasing Hormone Analogues in the Treatment of Prostate Cancer. In: Osborne, C.K. (eds) Endocrine Therapies in Breast and Prostate Cancer. Cancer Treatment and Research, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1731-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1731-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8974-6
Online ISBN: 978-1-4613-1731-9
eBook Packages: Springer Book Archive